EGAIN Corp EGAN
EGAIN Corp (EGAN) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $88.4M at a 36.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.26 |
| Retained earnings / assets | -1.969 |
| EBIT / assets | 0.03 |
| Equity / liabilities | 1.2 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| EGAN | EGAIN Corp | 4/9 | -3.25 | 5.5 | -4.7% |
| RDVT | Red Violet, Inc. | 6/9 | 13.55 | 64.7 | +20% |
| SNAL | Snail, Inc. | 2/9 | -6.48 | — | -3.8% |
| RAASY | Cloopen Group Holding Ltd | 2/9 | — | — | -2.5% |
| NTWK | NETSOL TECHNOLOGIES INC | 5/9 | 3.21 | 18.5 | +13.4% |
| SSTI | SOUNDTHINKING, INC. | 4/9 | -2.4 | — | +2.1% |
| SVCO | Silvaco Group, Inc. | 2/9 | -2.29 | — | +5.7% |
About EGAIN Corp
eGain Corporation engages in the development, license, implementation, and support of its customer service infrastructure software solutions in North America, Europe, the Middle East, Africa, and the Asia Pacific. It provides eGain AI Agent, which helps businesses to deploy enterprise-grade agentic solutions built on knowledge and guided actions; eGain AI Knowledge Hub to centralize knowledge, policies, procedures, situations, and best-practices, as well as guided and personalized answers to customers, agents, and field staff; and eGain Conversation Hub for scalable capabilities of digital-first interaction management within a modern, omnichannel desktop. The company also offers a cloud-based platform through subscription basis; professional services, such as consulting and implementation services, training services, and managed services. It serves customers in various industry sectors, financial services, the public sector, healthcare, telecommunications, and other highly regulated industries. The company was incorporated in 1997 and is headquartered in Sunnyvale, California.
FAQ
Is EGAN financially healthy?
EGAIN Corp's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does EGAN pay a dividend?
No, EGAIN Corp does not currently pay a dividend.
How profitable is EGAN?
In FY2025, EGAIN Corp had a net margin of 36.5% and a return on equity of 40.0%.
Is EGAN overvalued or undervalued?
EGAIN Corp trades at about 6.5× trailing earnings — below its 10-year norm (10-year range 5.5×–383.7×, median 55.3×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for EGAN?
The average Wall-Street price target for EGAIN Corp is $12.83, about 76.0% above the recent price, from 3 analysts.
Is EGAN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on EGAIN Corp: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone, a P/E of about 5.5×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.